Bioelectronics Corp
BioElectronics Corporation, an electroceutical company, engages in the development and sale of wearable, neuromodulation devices to mitigate neurological diseases and enhance quality of life worldwide. Its products include ActiPatch, a musculoskeletal pain therapy; Allay, a menstrual pain therapy; and Smart Insole, a heel pain therapy. The company also offers RecoveryRx, a medical device that pro… Read more
Bioelectronics Corp (BIEL) - Total Liabilities
Latest total liabilities as of March 2023: $16.14 Million USD
Based on the latest financial reports, Bioelectronics Corp (BIEL) has total liabilities worth $16.14 Million USD as of March 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bioelectronics Corp - Total Liabilities Trend (2013–2024)
This chart illustrates how Bioelectronics Corp's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Bioelectronics Corp Competitors by Total Liabilities
The table below lists competitors of Bioelectronics Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GIB Capital Group Inc
PINK:GIBX
|
USA | $33.13K |
|
Founders Bay Holdings
PINK:FDBH
|
USA | $7.53 Million |
|
Maxx Sports TV Inc
PINK:AMXX
|
USA | $3.87 Million |
|
Il2m International Corp
PINK:ILIM
|
USA | $2.56 Million |
|
Covista Communications Inc
PINK:CVST
|
USA | $10.83 Million |
|
Astra Veda Corporation
PINK:ASTA
|
USA | $2.48 Million |
|
EQM Technologies & Energy Inc
PINK:EQTE
|
USA | $23.04 Million |
|
Dragon Capital Grp
PINK:DRGV
|
USA | $249.05K |
Liability Composition Analysis (2013–2024)
This chart breaks down Bioelectronics Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 94.71 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bioelectronics Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bioelectronics Corp (2013–2024)
The table below shows the annual total liabilities of Bioelectronics Corp from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $17.45 Million | +4.99% |
| 2023-12-31 | $16.62 Million | +3.85% |
| 2022-12-31 | $16.01 Million | +5.29% |
| 2021-12-31 | $15.20 Million | -2.22% |
| 2020-12-31 | $15.55 Million | +4.21% |
| 2019-12-31 | $14.92 Million | +10.58% |
| 2018-12-31 | $13.49 Million | +20.60% |
| 2017-12-31 | $11.19 Million | +6.80% |
| 2016-12-31 | $10.47 Million | +6.28% |
| 2015-12-31 | $9.86 Million | +11.49% |
| 2014-12-31 | $8.84 Million | +4.86% |
| 2013-12-31 | $8.43 Million | -- |